NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) Stock
NASDAQ · NAMS
Key stats
- Market cap
- $2.48B
- Price / Earnings ratio
- -10.0x
- EPS (TTM)
- -$1.91
- Volume
- Loading
- 52-week high
- $42.21
- 52-week low
- $17.90
Source: third-party data provider, as of November 13, 2026
Compare with NAMS
Recent news

MarketBeat
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NAMSAugust 5, 2026
MarketBeat
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NAMS

Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NAMSAugust 5, 2026
Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NAMS

MarketBeat
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NAMSMay 8, 2026
MarketBeat
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NAMS

Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NAMSMay 7, 2026
Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NAMS
Technical indicators
- RSI 14
- 50.31
- MACD 12/26/9
- -0.69
- EMA 9 of MACD
- -0.78
- MACD histogram
- 0.09
- SMA 50
- $21.75
- Price below SMA 50
- EMA 50
- $22.07
- Price below EMA 50
- SMA 200
- $29.27
- Price below SMA 200
- EMA 200
- $28.33
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Strong Sell0
Sell0
Hold0
Buy4
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
131M87M43M0
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
1B685M342M0
Revenue to Profit
2025$26.4M
Revenue$0.0
Cost of revenue$22.5M
Gross profit$0.0
Operating expenses$-203.8M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

MarketBeat
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NAMSAugust 5, 2026
MarketBeat
NewAmsterdam Pharma Maps Obicetrapib Strategy as PREVAIL Interim Nears
NAMS

Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NAMSAugust 5, 2026
Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates
NAMS

MarketBeat
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NAMSMay 8, 2026
MarketBeat
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
NAMS

Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NAMSMay 7, 2026
Zacks Investment Research
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NAMS

InvestorPlace
3 Drug Stocks to Watch as Alzheimer's Clinical Trials End
NAMSFebruary 24, 2023
InvestorPlace
3 Drug Stocks to Watch as Alzheimer's Clinical Trials End
NAMS
About NewAmsterdam Pharma Company N.V. Ordinary Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees100
CEODr. Michael Harvey Davidson FACC, Facp., M.D.
IPO DateNov 23, 2022
HeadquartersNaarden, Netherlands
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President & Executive Director | 1956 |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer | 1974 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 1954 |
| Mr. Robert W. Gunning C.P.A., CGMA | Principal Accounting Officer, VP & Controller | 1971 |
| Mr. Matthew Philippe | Executive VP & Head of Investor Relations | — |
| Mr. Michael F. Marino Esq. | Chief Legal Officer & Corporate Secretary | 1976 |
| Mr. Chris Deluzio | Executive Vice President of Sales Enterprise Operations | — |
| Ms. Maryellen McQuade | Chief People Officer | — |
| Ms. Juliette Audet M.B.A., M.Sc. | Chief Strategy & Business Officer | 1987 |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer | 1967 |
Fundamentals
Valuation
Price-to-sales ratio30.55
Price-to-book value3.22
Profitability
Return on Equity-38.00%
Return on Assets-35.00%
Return on Sales-3644.00%
Gross margin (latest quarter)88.28%
EBITDA$-293.61M
Trading
Average volume1,608,957
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.31
- MACD 12/26/9
- -0.69
- EMA 9 of MACD
- -0.78
- MACD histogram
- 0.09
- SMA 50
- $21.75
- Price below SMA 50
- EMA 50
- $22.07
- Price below EMA 50
- SMA 200
- $29.27
- Price below SMA 200
- EMA 200
- $28.33
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $42.00
- Average
- $50.25
- High
- $61.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -21.7 | +23.2 | ||||||||||
| 2023 | +19.5 | +2.9 | +2.2 | +5.2 | -5.5 | -13.8 | -4.0 | -8.8 | -11.3 | +6.9 | +5.4 | +15.3 |
| 2024 | +71.3 | +9.8 | +0.5 | +2.1 | -14.7 | +1.5 | -16.8 | -4.9 | +4.3 | -1.6 | +11.4 | +30.9 |
| 2025 | -14.1 | -1.7 | +1.0 | +4.1 | -9.6 | -4.3 | +19.7 | +13.0 | +15.5 | +29.3 | +11.6 | -11.4 |
| 2026 | -11.6 | +12.3 | -2.5 | -13.0 | +18.5 | +6.6 | -21.0 | -7.8 | -2.4 | -17.0 | -1.9 |
Compare stocks
Market cap
$2.48B
-
-
-
Price / Earnings ratio
-10.00
-
-
-
Price / Sales ratio
30.55
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,608,957
-
-
-
Earnings per share
$-1.91
-
-
-



